Ashland Posts 7% Sales Growth to $497M in Q3, Reaffirms Full-Year Targets
ASH sits 47% above its 52-week low of $46.295.
Summary
Ashland's Q3 sales climbed 7% to $497M, with growth across all units. Net income swung to a $16M profit. Full-year sales and EBITDA guidance were reaffirmed, though the adjusted EPS outlook was trimmed on tax items.
Key Events · Earnings and Guidance · ASH
-
Q3 Sales Rise 7% to $497M
Revenue climbed 7% year-over-year to $497 million, driven by volume growth in every business unit. Life Sciences led the charge with an 11% increase, followed by Personal Care up 5%, Specialty Additives up 4%, and Intermediates up 12%.
-
Net Income Swings to $16M Profit
Net income reached $16 million, or $0.35 per diluted share, a sharp turnaround from the prior-year quarter's $742 million loss, which included a $706 million goodwill impairment. Adjusted EBITDA came in at $109 million, down 4% from $113 million.
-
Full-Year Guidance Reaffirmed
Management reaffirmed its fiscal 2026 sales outlook of $1,835-$1,870 million and Adjusted EBITDA guidance of $385-$400 million, underscoring confidence in sustained demand and operational improvements.
-
Adjusted EPS Outlook Trimmed on Tax
The adjusted diluted EPS growth forecast was revised to low-to-mid single digits from mid-to-high single digits, reflecting a higher tax rate due to unfavorable discrete items.
Analysis · ASH · Trade & Services
Broad-based demand fueled a 7% revenue increase to $497 million, with Life Sciences delivering double-digit gains. The bottom line swung to a $16 million profit from a $742 million loss a year ago, when a large goodwill impairment weighed heavily. Adjusted EBITDA edged 4% lower to $109 million, yet the company stood by its full-year sales and EBITDA guidance—a signal of confidence in the ongoing recovery. The only soft spot was a trimmed adjusted EPS outlook, reflecting a higher tax rate. Set against activist pressure and a recently renewed credit facility, these results highlight operational momentum that bolsters management's standalone strategy.
At the time of this filing, ASH was trading at $68.01 on NYSE in the Trade & Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $46.30 to $72.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.